- Home
- Products
- Customized ADCs
- CD80
- Anti-CD80 (Galiximab)-MC-Vc-PAB-MMAE ADC
Anti-CD80 (Galiximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-959)
This ADC product is comprised of an anti-CD80 monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD80
- Alternative Names
- CD80; CD80 molecule; CD28LG, CD28LG1, CD80 antigen (CD28 antigen ligand 1, B7 1 antigen) , CD80 molecule; T-lymphocyte activation antigen CD80; B lymphocyte activation antigen B7; B7 1; B7.1; activation B7-1 antigen; costimulatory factor CD80; CTLA-4 counnternalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Target Entrez Gene ID
- 941
- Target UniProt ID
- P336815
- Overview
- The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may pl
- Overview
- Chimeric Anti-CD80 IgG1-lambda antibody, Galiximab
- Generic name
- Galiximab
- Host animal
- Primate
- Species Reactivity
- Human
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IL13RA2-Mc- ADC (CAT#: ADC-W-010)
- Anti-RhD (Atorolimumab)-SMCC-DM1 ADC (CAT#: ADC-W-1718)
- Anti-CEACAM8 (Besilesomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2207)
- Anti-EpCAM-sulfo-SPDB-DM4 ADC (CAT#: ADC-W-544)
- Anti-CTAA16.88 (Votumumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2045)
- Anti-CD22-SMCC-DM1 ADC (CAT#: ADC-W-2527)
- Anti-LY6E-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-305)
- Anti-CD79b-BMPEO-DM1 ADC-1 (CAT#: ADC-W-025)
- Anti-TNFRSF8 (Brentuximab)-DBCO-MMAF ADC-11 (CAT#: ADC-W-263)
- Anti-TNFRSF8-Mc-VC-PABC-MMAE ADC-12 (CAT#: ADC-W-344)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-959. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-960 | Anti-CD80 (Galiximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-956 | Anti-CD80 (Galiximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-958 | Anti-CD80 (Galiximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-961 | Anti-CD80 (Galiximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-957 | Anti-CD80 (Galiximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2602 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2587 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2608 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2562 | Anti-MSLN (Anetumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2551 | Anti-CD74-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2529 | Anti-CD22-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2586 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.